Harpoon Therapeutics, Inc.
HARPNASDAQHealthcare
$23.01
+$0.02(+0.09%)
Market Cap$865079358
P/E Ratio—
52W High$23.21
52W Low$3.11
Harpoon Therapeutics, Inc. (HARP) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
HARP · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2024Report Date: Mar 25, 2024EPS Actual
-$5.50
Est. -$0.50 · -1000.0%
Revenue
—
Fiscal Period
Q1 FY2024
FY ends December
Report Date
Mar 25, 2024
After Market Close
▼ Miss EPS
HARP reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2024 | May 9, 2024 | — | — | — | — | — | — |
| ▼ Q1 FY2024 | Mar 25, 2024 | -$0.50 | -$5.50 | -1000.0% | — | — | — |
| ▲ Q4 FY2023 | Nov 13, 2023 | -$3.09 | -$0.46 | +85.1% | $0.00B | — | — |
| ▲ Q3 FY2023 | Aug 9, 2023 | -$4.30 | $0.30 | +107.0% | $0.02B | $0.01B | +292.6% |
| ▲ Q2 FY2023 | May 11, 2023 | -$4.20 | -$3.10 | +26.2% | $0.01B | $0.00B | +78.4% |
| ▼ Q1 FY2023 | Mar 27, 2023 | -$4.30 | -$5.50 | -27.9% | $0.00B | $0.01B | -41.9% |
| ▲ Q4 FY2022 | Nov 14, 2022 | -$6.00 | -$3.50 | +41.7% | $0.01B | — | — |
| ▲ Q3 FY2022 | Aug 10, 2022 | -$5.50 | -$5.30 | +3.6% | $0.01B | — | — |
Q2 FY2024
May 9, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2024
Mar 25, 2024Miss
EPS Actual
-$5.50
EPS Est.
-$0.50
EPS Surpr.
-1000.0%
Revenue
—
Q4 FY2023
Nov 13, 2023Beat
EPS Actual
-$0.46
EPS Est.
-$3.09
EPS Surpr.
+85.1%
Revenue
$0.00B
Q3 FY2023
Aug 9, 2023Beat
EPS Actual
$0.30
EPS Est.
-$4.30
EPS Surpr.
+107.0%
Revenue
$0.02B
Q2 FY2023
May 11, 2023Beat
EPS Actual
-$3.10
EPS Est.
-$4.20
EPS Surpr.
+26.2%
Revenue
$0.01B
Q1 FY2023
Mar 27, 2023Miss
EPS Actual
-$5.50
EPS Est.
-$4.30
EPS Surpr.
-27.9%
Revenue
$0.00B
Q4 FY2022
Nov 14, 2022Beat
EPS Actual
-$3.50
EPS Est.
-$6.00
EPS Surpr.
+41.7%
Revenue
$0.01B
Q3 FY2022
Aug 10, 2022Beat
EPS Actual
-$5.30
EPS Est.
-$5.50
EPS Surpr.
+3.6%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $1.54 | $1.54 | $1.54 | 1 |
| Q2 FY2024 | $1.34 | $1.34 | $1.34 | 1 |
| Q1 FY2024 | $1.58 | $1.58 | $1.58 | 1 |
| Q4 FY2023 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2023 | $0.00 | $0.00 | $0.00 | 3 |
| Q1 FY2022 | $1.43 | $1.43 | $1.43 | 14 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2023 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2022 | $0.0B | $0.0B | $0.0B | 11 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2024 | Mar 25, 2024 | -1000.0% | $23.01 | — | — |
| ▲ Q4 FY2023 | Nov 13, 2023 | +85.1% | $6.33 | $7.54 | +19.12% |
| ▲ Q3 FY2023 | Aug 9, 2023 | +107.0% | $7.90 | $8.09 | +2.41% |
| ▲ Q2 FY2023 | May 11, 2023 | +26.2% | $7.96 | $8.20 | +3.02% |
| ▼ Q1 FY2023 | Mar 27, 2023 | -27.9% | $6.73 | $6.53 | -2.97% |
| ▲ Q4 FY2022 | Nov 14, 2022 | +41.7% | $8.20 | $7.90 | -3.66% |
| ▲ Q3 FY2022 | Aug 10, 2022 | +3.6% | $20.70 | $21.60 | +4.35% |
| ▼ Q2 FY2022 | May 12, 2022 | -29.2% | $17.80 | $18.60 | +4.49% |
Q1 FY2024—
Report Date
Mar 25, 2024
EPS Beat/Miss
-1000.0%
Price Before
$23.01
Price After
—
Q4 FY2023+19.12%
Report Date
Nov 13, 2023
EPS Beat/Miss
+85.1%
Price Before
$6.33
Price After
$7.54
Q3 FY2023+2.41%
Report Date
Aug 9, 2023
EPS Beat/Miss
+107.0%
Price Before
$7.90
Price After
$8.09
Q2 FY2023+3.02%
Report Date
May 11, 2023
EPS Beat/Miss
+26.2%
Price Before
$7.96
Price After
$8.20
Q1 FY2023-2.97%
Report Date
Mar 27, 2023
EPS Beat/Miss
-27.9%
Price Before
$6.73
Price After
$6.53
Q4 FY2022-3.66%
Report Date
Nov 14, 2022
EPS Beat/Miss
+41.7%
Price Before
$8.20
Price After
$7.90
Q3 FY2022+4.35%
Report Date
Aug 10, 2022
EPS Beat/Miss
+3.6%
Price Before
$20.70
Price After
$21.60
Q2 FY2022+4.49%
Report Date
May 12, 2022
EPS Beat/Miss
-29.2%
Price Before
$17.80
Price After
$18.60
Avg Beat Reaction+5.05%
Avg Miss Reaction+0.76%
Beat Rate5 / 8 quarters
Largest Move+19.12% (Q4 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: HARP ends December
Harpoon Therapeutics, Inc. (HARP) most recently reported earnings on March 25, 2024 for Q1 FY2024, posting EPS of $-5.50 — missing the analyst consensus of $-0.50 by -1000.0%. The next HARP earnings date is expected around September 1, 2026.
Each quarter, investors track HARP earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. HARP revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
HARP's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
HARP earnings · 5 questionsHarpoon Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. HARP typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; HARP historically reports after market close (AMC).
HARP earnings datewhen is HARP earningsHARP next earnings datewhen does HARP report earningsHARP earnings calendar
▸ Source: FMP · Harpoon Therapeutics, Inc. SEC filings · US GAAP · Harpoon Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026